Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3342 results about "Combination therapy" patented technology

Combination therapy or polytherapy is therapy that uses more than one medication or modality (versus monotherapy, which is any therapy taken alone). Typically, these terms refer to using multiple therapies to treat a single disease, and often all the therapies are pharmaceutical (although it can also involve non-medical therapy, such as the combination of medications and talk therapy to treat depression). 'Pharmaceutical' combination therapy may be achieved by prescribing/administering separate drugs, or, where available, dosage forms that contain more than one active ingredient (such as fixed-dose combinations).

Combination therapies for the treatment of cancer

Provided is combination therapies that involve a construct has a TIGIT-binding moiety and a PVRIG-binding moiety and a KRAS G12C inhibitor for treating cancer with KRAS G12C mutations. In some cases, the construct is a multispecific antibody or a bispecific antibody that recognizes PVRIG and TIGIT.
Owner:D3 BIO (WUXI) CO LTD

Combination therapies with KRAS modulators

Provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of an immunomodulator inhibitor and a compound of Formula (II).
Owner:QUANTA THERAPEUTICS INC

Combination therapy for cancer treatment

The present invention provides methods of treating a cancer patient with an inhibitor of KRAS and an anti-CCR8 antibody. These methods are useful for treating a number of cancers, including pancreatic, colorectal, and lung cancers.
Owner:AMGEN INC

Combination therapies

The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
Owner:MIRATI THERAPEUTICS INC

Small molecule inhibitors of repeat associated non-aug (RAN) translation and combination therapies

The present disclosure provides methods, uses, kits, and compositions comprising a compound of Formula (I), and either a second compound of Formula (I) or a compound of Formula (II). In one aspect, the methods are for treating a neurological disease associated with repeat expansions and / or RAN protein accumulation, reducing the level of one or more repeat associated non-AUG (RAN) proteins, and reducing the accumulation of RAN proteins in a subject and / or biological sample. Exemplary diseases associated with repeat expansions include, but are not limited to, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, myotonic dystrophy type 1, myotonic dystrophy type 2, spinocerebellar ataxia, Alzheimer's disease, Huntington's disease, Fragile X Tremor Ataxia Syndrome, and Fragile XE syndrome.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Methods of treating cancer

PCT designated stage expiredWO2025080769A1Capsule deliveryAmide active ingredientsOncologySolid tumor
Owner:FOGHORN THERAPEUTICS INC

Combination therapy for treating hematological cancers

PCT designated stage expiredWO2024249769A2Organic active ingredientsOncologyCombination therapy
The present disclosure features a combination therapy useful for the treatment of AML and related hematological cancers.
Owner:FOGHORN THERAPEUTICS INC

Combination therapy including a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

The present invention provides combination therapy that includes an KRASG12C inhibitor, such asor a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
Owner:AMGEN INC

Pharmaceutical composition for treating diffuse large B-cell lymphoma and application thereof

The invention discloses application of an anti-CD20 antibody drug conjugate or a drug combination thereof in preparation of a drug for treating diffuse large B-cell lymphoma. The drug combination comprises the anti-CD20 antibody drug conjugate, gemcitabine and oxaliplatin, the anti-CD20 antibody drug conjugate or the drug combination therapy containing the anti-CD20 antibody drug conjugate has a better curative effect compared with the existing clinical second-line standard therapy.
Owner:ZHEJIANG TERUISI PHARMA INC

Combination therapy for lung cancer

The disclosure provides a method of treating a human subject afflicted with lung cancer (e.g., non-small cell lung cancer (NSCLC)) with a programmed death-1 (PD-1) pathway inhibitor (e.g., an anti-PD-1 antibody) and a concurrent chemoradiotherapy (CCRT, e.g., a platinum doublet chemotherapy (PDCT) and a radiation therapy) followed by a combination of a PD-1 pathway inhibitor (e.g., an anti-PD-1 antibody) and a lymphocyte activation gene-3 (LAG-3) antagonist (e.g., an anti-LAG-3 antibody). In some aspects, the method comprises a recovery period that begins upon completion of the treatment with the PD-1 pathway inhibitor and the CCRT and ends at the start of the treatment with the combination of the PD-1 pathway inhibitor and the LAG-3 antagonist.
Owner:BRISTOL MYERS SQUIBB CO

Combination of a cell therapy and a gamma secretase inhibitor

Provided herein are combination therapies involving administration of an immunotherapy involving a cell therapy, such as a T cell therapy, and an inhibitor of gamma secretase. Also provided are methods for engineering, preparing, and producing the cells, compositions containing the cells and / or gamma secretase inhibitor, and kits and devices containing and for using, producing and administering the cells and / or gamma secretase inhibitor, such as in accord with the provided combination therapy methods.
Owner:JUNO THERAPEUTICS INC +1

Combination therapies for breast cancer

The present application discloses combinations for treating estrogen receptor-positive and HER2-positive breast cancer patients. The combinations comprise pertuzumab and trastuzumab (e.g. a fixed dose combination of pertuzumab and trastuzumab, PH FDC) plus giredestrant. In one embodiment, the combination further includes a CDK4 / 6 inhibitor, such as abemaciclib or palbociclib.
Owner:GENENTECH INC +1

Asymmetric drug interaction prediction method based on diffusion diagram attention network

The invention provides an asymmetric drug interaction prediction method based on a diffusion diagram attention network, and relates to the technical field of drug interaction prediction.The method comprises the steps that a directed graph network is constructed by using chemical structure features of drug molecules, and features are extracted from drug applying and receiving perspectives through a two-way diagram attention network; therefore, the asymmetry between the drugs is effectively represented. Furthermore, a diffusion model is introduced to carry out noise injection and de-noising processing on a graph structure, so that the adaptability of the model to sparse data and the robustness of feature extraction are remarkably enhanced. Finally, multi-modal features are fused through a deep neural network, and high-precision prediction of drug interaction is realized. Compared with the prior art, the method has the advantages that the prediction accuracy exceeds that of the prior art, the dependence on labeled data is greatly reduced, the feasibility and generalization ability of the model in practical application are greatly improved, and a new technical path is provided for safety evaluation and precise medical research of drug combination therapy.
Owner:XIAMEN UNIV OF TECH

Combination therapies for the treatment of cancer

Provided are methods of treating a cellular proliferative disorder (e.g., cancer) comprising administering: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I) : wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.
Owner:MERCK SHARP & DOHME LLC +1

Anti-CD20 x Anti-CD28 combination therapies

Provided herein are novel anti-CD20 x anti-CD28 antibodies and methods of using such antibodies for the treatment of B-cell malignancies. Subject anti-CD20 x anti-CD28 antibodies are capable of agonistically binding to CD28 costimulatory molecules on T cells and CD20 on tumor cells. Thus, such antibodies enhance anti-tumor activity at tumor sites. The subject antibodies provided herein are particularly useful in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-CD20 x anti-CD79b antibodies) for the treatment of B-cell malignancies.
Owner:XENCOR INC +3

Methods of treating a ras related disease or disorder

The disclosure features methods of treating RAS disorders using safe and effective doses of Compound A, or a pharmaceutically acceptable salt thereof. The disclosure also features methods of treating RAS disorders including combination therapies comprising Compound A, or a pharmaceutically acceptable salt thereof, and additional therapeutic agent. Compound A is a compound having the following structure:
Owner:REVOLUTION MEDICINES INC

Wee1 inhibitor combination therapy

Disclosed herein is use of a combination of Compound (A) (azenosertib), or a pharmaceutically acceptable salt thereof, and a KRAS G12C inhibitor, such as sotorasib or adagrasib, or a pharmaceutically acceptable salt thereof, for treating a disease or condition, such as a colorectal, pancreatic and / or non-small cell lung cancer.
Owner:ZENO MANAGEMENT INC

Disease modifying Anti-rheumatic drug combination therapies

PCT designated stage expiredWO2025099187A1AntipyreticDigestive systemAutoimmune conditionProgressive disorder
The invention provides combination therapies comprising disease modifying anti-rheumatic drugs and mitochondrial complex I modulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders, for example autoimmune diseases such as arthritis.
Owner:ISTESSO 2 LTD

Combination therapy using VPS34 inhibitors

Described herein, in part, are methods of treating cancer in patients in need thereof, comprising administering to the patient a VPS34 inhibitor and one or more additional therapeutic agents, such as a STING agonist.
Owner:DECIPHERA PHARMACEUTICALS LLC

A pharmaceutical composition for treating PIK3CA mutation colon cancer and its application

This invention belongs to the field of biomedical technology, specifically disclosing a pharmaceutical composition for treating PIK3CA-mutated colorectal cancer and the application of Alpelisib and Menin-MLL complex inhibitors in combination therapy for colorectal cancer. Experimental results show that the combined use of Alpelisib and Menin-MLL 1 / 2 interaction inhibitors can synergistically inhibit the growth of PIK3CA-mutated colorectal cancer PDX tumors and even induce tumor regression, demonstrating better therapeutic effects than Alpelisib alone. The combination of the two has a synergistic therapeutic effect.
Owner:AFFILIATED HOSPITAL OF JINING MEDICAL UNIV

Chiral cyclic peptide and manganese ion coordination nano assembly and preparation method and application thereof

The invention provides a coordination nano assembly of chiral cyclopeptide and manganese ions as well as a preparation method and application of the coordination nano assembly. According to the method, a manganese superoxide dismutase protein structural domain and a unique tumor microenvironment of melanoma high tyrosinase are combined, and polypeptide sequences L-YD-hL-DD-h, L-YL-HL-DL-H and D-yD-hD-dD-h with different chirality are designed for the first time; the chirality of the polypeptide is regulated and controlled, the in-vivo circulation stability and the cell entry efficiency of the nano assembly are improved, the coordination self-assembly of manganese and different chiral cyclopeptides is realized, and the in-situ oxidation of an in-vivo tumor microenvironment is simulated for photo-thermal therapy and cell membrane coating. The method disclosed by the invention is simple, mild in experimental condition and easy to operate, the prepared cell membrane coated nano assembly not only has long circulation stability and high cell entry efficiency, but also can realize mild photo-thermal therapy through in-situ oxidation, releases manganese ions to activate a CGAS-STING pathway for immunotherapy of tumors, and has a wide application prospect. The potential application value is realized in the field of combined treatment of tumors.
Owner:TONGJI UNIV

Intermittent dosing regimen for azenosertib in treating cancer

Provided herein is, among other things, is a method of treating cancer using an improved intermittent dosing regimen for Azenosertib, or a pharmaceutically acceptable salt thereof, administration to achieve a highly efficacious, safe and tolerable dosing regimen to treat many different types of cancers. In one aspect, the method of treating cancer comprises administering a daily dose of Azenosertib, or a pharmaceutically acceptable salt thereof, (e.g., greater than about 350 mg) in accordance with an improved intermittent dosing cycle, wherein the intermittent dosing cycle comprises one or more dosing weeks with each dosing week comprising between about 2-7 consecutive dosing days and between about 1-7 days without dosing. In some embodiments, the intermittent dosing cycle is repeated wherein the dosing weeks are separated by a break of one, two or more weeks. In some aspects, Azenosertib, or a pharmaceutically acceptable salt thereof, is administered as a combination therapy.
Owner:ZENO MANAGEMENT INC